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replication activities of v84(C4) and c84 were 21.3 and 10.2% of v84(U4). This difference came from their
polymerase binding activity. When all the eight genome segments of WSN strain were changed to U4, the
virus titer was 760 times higher than the wild type. However, its pathogenicity in mice was lower than the
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Inﬂuenza A virus contains eight single-stranded (ss) RNA
segments of negative polarity as its genome and RNA dependent
RNA polymerase (RdRp) as a virion component (Palese and Shaw,
2007). Inﬂuenza virus RdRp catalyzes both transcription [synthesis of
plus-strand mRNA containing the host cell-derived cap-1 structure at
the 5′-terminus and a poly(A) tail at the 3′-terminus] and replication
[synthesis of full-length plus-strand complementary RNA (cRNA) and
the cRNA-dependent synthesis of minus-strand viral RNA (vRNA)]
(Ishihama and Nagata, 1988). The viral RdRp also adds poly(A) tail at
the 3′-termini of mRNA (Pritlove et al., 1998). Recently, we puriﬁed
the recombinant inﬂuenza virus RdRp from insect cells and demon-
strated all of these activities in our RdRp in vitro (Zhang et al., 2010a).
All inﬂuenza A virus RNA genome segments have 13 and 12
conserved nucleotides at their 5′ and 3′-termini, respectively. These
conserved sequences are necessary for the transcription promoter and
the replication origin (Fodor and Brownlee, 2002; Neumann et al.,
2004). This structurewasﬁrst characterized as a “pan-handle structure”
(Desselberger et al., 1980; Hsu et al., 1987) and later as a “fork model”
(Fodor et al., 1995), and ﬁnally the “cork screw model” was proposed(Flick and Hobom, 1999). A series of mutational analyses of the 5′ and
3′-termini of the genome sequences of inﬂuenza A viruses agreed with
the “cork screwmodel” (Brownlee and Sharps, 2002; Crow et al., 2004;
Leahy et al., 2001a,b). However, the RNA duplex of the 5′ and 3′-RNA
fragments agreed with the “pan-handle structure” (Lee et al., 2003),
speculating that the “cork screw” is formed by complex formation with
PB1. The “cork screw” structure serves both for the transcription
promoter (Fodor and Brownlee, 2002) and the replication origin (Crow
et al., 2004; Deng et al., 2006).
In the conserved 3′-terminal sequence, there is single nucleotide
variation at the 4th position from the end; i.e., U (U4) or C (C4).
Inﬂuenza virus A/WSN/33 contains C in PB2, PB1, PA, and NA at this
position, while U is present in the other genomes (Desselberger et al.,
1980; Robertson, 1979). When NA genome contained U4 transcrip-
tion promoter/replication origin (promoter/origin), its transcription
was higher than when it contained C4, and the titer of this virus was
higher than that containing C4 (Lee and Seong, 1998), indicating that
the U4 promoter/origin has stronger activity in the cells. The mRNA
expression of inﬂuenza A/Udorn (H3N2) was found to be as follows;
M (U4)NNS (U4)NNP (U4)NNANHA (U4)Npolymerase subunits
which had C4 (Hatada et al., 1989). However, the roles and the
mechanisms underlying of the two different promoters/origins of the
inﬂuenza virus genome are not clear.
In this paper, we directly analyzed the promoter/origin activity of
U4 and C4 vRNA and cRNA in vitro using the puriﬁed inﬂuenza virus
RdRp (Zhang et al., 2010a) and compared their activity in vitro, their
replicon activity, their effects on virus growth in the cells and their
pathogenicity mice.
Fig. 2. In vitro transcription/replication of v84(U4), v84(C4), and c84 templates. In vitro
transcription/replication activities of v84(U4), v84(C4), and c84 were tested without
(de novo) or with 0.1 mM ApG (ApG) or 0.01 mg/ml globin mRNA (mRNA). The
products were analyzed by 6% PAGE containing 8 M urea. The representative
autoradiogram is indicated in A, and the relative polymerase activity is indicated in B.
The graphs (B) were constructed from the mean and standard deviation (error bar) of
three independent experiments. The positions of the transcripts are indicated on the
left (See Fig. S2), and that of the v84 size marker (M) is indicated on the right of the
ﬁgure (A).
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Comparison of the U4 and C4 promoter activity in vitro
Recently, we puriﬁed the inﬂuenza virus RdRp from insect cells
(Fig. S1A). Inﬂuenza virus transcription is reconstituted in vitro using
the puriﬁed RdRp and the model vRNA templates which carry both 5′
and 3′ NTR of the inﬂuenza vRNA with globin mRNA, and its
replication is reconstituted in vitro using model v- and cRNA
templates with or without ApG (Honda et al., 2002; Newcomb et al.,
2009; Zhang et al., 2010a).
Inﬂuenza viruses A/WSN/33 and A/PR8/34 contain various
combinations of U4 and C4 genome templates. The replicon and
template (promoter and origin) activities of two different 3′-ends of
vRNA and cRNA templates were compared in replicon and in vitro
transcription assays. The replicon activities of NS(U4)luc and NS(C4)
luc were compared in a PR8 replicon system (Fig. 1). The replicon
activity of NS(C4)luc was 28±6.0% of that of NS(U4)luc. The replicon
activity indicates transcription activity. Therefore, in order to analyze
the difference in transcription/replication (promoter/origin) activity
of v84(U4), v84(C4) and c84 templates precisely, we compared their
activity in vitro using the puriﬁed inﬂuenza virus RdRp (Fig. 2).
The puriﬁed inﬂuenza virus RdRp speciﬁcally transcribed and
replicated v- and c84 RNA (Fig. 2) (Zhang et al., 2010), but did not
utilize homopolymeric RNA templates with dinucleotide primers (Fig.
S1B). With ApG, 84 nt RNAwere produced from v84, and 84 and 81 nt
RNA were produced from c84 (Zhang et al., 2010b). The relative ApG-
primed replication activities of v84(C4) and c84 were 23.8±1.6 and
7.81±0.24% of that of v84(U4), respectively.
Because of the cost of globin mRNA, we ﬁrst titrated the amount of
globin mRNA for v84(U4) and used 0.01 mg/ml of globin mRNA for
the transcription in vitro (Fig. S3). With globin mRNA, 98 and 96 nt
RNA were produced from v84 and c84, and the relative globin mRNA-
primed transcription activities of v84(C4) and c84were 36.9±2.6 and
6.81±0.57% of that of v84, respectively. Without primers, 83 nt RNA
along with some 84 and 82 nt RNAwere produced from v84 and 81 nt
RNA were produced from c84, and the relative de novo replication
activities of v84(C4) and c84were 21.3±0.65 and 10.2±0.74% of that
of v84(U4), respectively.
The inﬂuenza RdRp initiated from the C at the 2nd position from
the 3′-end of the genome using 10–15 nucleotide cap-1 primers
(Plotch et al., 1979). Globin mRNA used in this experiment were
mixture of mRNA extracted from rabbit reticulocytes. When the
different lot of globin mRNA from Sigma was used, only 96 nt
products were observed (Fig. S3). According to the proposed inﬂuenza
virus transcription initiation scheme (Fodor and Brownlee, 2002), the
13 nt RNA primer of rabbit β globin mRNA (m7GmACACUUGCUUUU,0
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Fig. 1. The replicon activity of NS(U4) and NS(C4). Replicon activity of NS(U4)luc and
NS(C4)luc was measured as luciferase activity. The mean relative activity and standard
deviation (error bar) were calculated from three independent experiments.GenBank; M10843) produced the 96 nt products and that the 16 nt
RNA primer of rabbit α globin mRNA (m7GmACACUUCUGGUCCA,
GenBank; V00875) produced the 98 nt products, respectively.
In order to conﬁrm that the 98 and 96 nt products of globinmRNA-
primed transcription of c84 were transcribed from c84 and not from
v84which was the de novo initiation products of c84, the single-round
transcription was performed with heparin (Fig. 3). The sensitivity to
heparin was tested for ApG-primed and de novo replication of v84
(4U) and c84 templates and 50 μg/ml heparin was used for the
condition of the single-round transcription of c84 (Fig. S4) (Zhang
et al., 2010a). Both 96 and 98 nt products were transcribed from c84
with 0.5 μg globin mRNA in the single-round transcription (Fig. 3),
and we concluded that c84 also served as the template for globin
mRNA primer.
Polymerase binding afﬁnity of U4 and C4 promoter/origin
In order to ﬁnd out the mechanism of differences of template
activity between v84(U4) and v84(C4), we compared their binding
afﬁnity to RdRp by the competitive UV-crosslink assay (Fig. 4, S5).
First, 0.2 pmol [32P]v84(U4) was used as the probe (Fig. 4A). The 50%Fig. 3. Globin mRNA-primed single-round transcription of c84. Inﬂuenza virus RdRp
(5 μM), 10 μMof c84 and 0.01 mg/ml globinmRNAwere incubated without (−) or with
50 μg/ml heparin. The transcripts were analyzed by 6% PAGE containing 8 M urea. The
size of the transcripts is indicated on the left. The 98 and 96 nt products of the single-
round transcription are indicated by arrowheads.
Fig. 4. Competitive UV-crosslink of v84(U4) and v84(C4). A and C: The representative autoradiogram. Inﬂuenza virus RdRp (0.2 pmol) were UV-crosslinked with 0.2 pmol [32P]v84
(4U) (A and B) and [32P]v84(4C) (C and D) and the indicated amount of competitive v84(4U) or v84(4C). The crosslinked PB1 is mapped by superimposing of the autoradiogram
with the Coomassie brilliant blue stained PAGE (see Fig. S5). The competitive UV-crosslink graph was drawn from three independent experiments (B and D). The positions of RdRp
subunits are indicated on the left (A and C).
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Fig. 5. Growth kinetics of AllU4, AllC4, NAU4, and WSNwt. Multistep growth of AllU4,
AllC4, NSU4, NAU4 and WSNwt was measured as indicated in Materials and methods.
The mean and standard deviation (error bar in the graph) of each plaque titer were
calculated from three independent experiments.
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(U4), 0.2 pmol. That of v84(C4) was 0.45 pmol. In reverse, 0.2 pmol
[32P]v84(C4) was used as the probe (Figs. 4C,D). The 50% competition
of v84(C4) and v84(U4) was 0.51 pmol and 0.2 pmol, respectively. In
conclusion, the binding activity of v84(U4) is 2.4 times higher than
that of v84(C4).
Effect of the U4 and C4 promoters on viral replication
In order to test the effect of U4 and C4 promoter/origin on viral
replication in the cell, the virus with a C at the 4th position from the 3′-
end (AllC4) and one with a U at the same position (AllU4), and the wild
type (WSNwt) were reconstituted by the 12 plasmid transfection
methods (Neumann et al., 1999). WSN mutants which had U4 in NS
genome (NSU4) and U4 in NA (NAU4) genome were also made. At 72 h
after transfection, the viruses were harvested, and their titers were
measured by a plaque forming assay in MDCK cells. Their plaque sizes
were similar (data not shown). The growth kinetics of AllU4, AllC4,
NAU4,NSU4 andWSNwt viruseswere examined inMDCKcells. The cells
were infectedwith these viruses at anMOI of 0.01, and the supernatants
were collected at 0, 8, 16, 24, 36, 48, and 60 h after infection. The virus
titerswere analyzedbyaplaque formingassay inMDCKcells (Fig. 5). The
growth curves ofWSNwt, NSU4 andAllC4were similar. The titer of AllC4
was slightly less thanWSNwt, but it caughtup at 60 h after infection. The
viruses were not released until 8 h post infection (pi), after which the
viruses were released into the media. The growth kinetics of AllU4 and
WSNwt showed similar patterns and plateaued at 48 h pi. The titer of
AllU4 was higher than that of WSNwt after 24 h pi. The titer of NAU4 at
8 to 24 h was higher than others, but ﬁnally converged between AllU4
andWSNwt. The titers at 60 hpi,when the growth curveshadplateaued,
were 6.58±4.55×108 PFU/ml for AllU4, 1.30±0.85×106 PFU/ml for
AllC4, 5.56±0.56×107 PFU/ml for NAU4, 0.94±0.2×106 PFU/ml for
NSU4 and 0.87±0.39×106 PFU/ml for WSNwt.
After the growth kinetic analysis, genome RNAwere extracted and
cloned by RACE to determine their sequences at the 3′-end in order to
conﬁrm the absence of mutations in the 3′-end of the genomes.
During the growth kinetic experiment, all the viruses kept their 3′
sequences as designed (data not shown).Pathogenicity in mice
The titer of AllU4 was higher than WSNwt and AllC4 in cultured
cells. Finally, the pathogenicity of AllU4 and AllC4 was compared with
WSNwt in Balb/c mice (Fig. 6). 105 and 104 PFU of AllC4 did not kill
mice at all. All the mice were killed when they were infected with
105 PFU of WSNwt and with 106 PFU of AllU4. 105 PFU of AllU4 killed
50% of mice. LD50 of mouse nasal infection was calculated by Reed
and Muench's (1938) method. The LD50 of WSNwt and AllU4 are
1×104 PFU and 1×105 PFU, respectively. That of AllC4 is not available
because the high titer virus was not obtained.
Interferon β promoter activity
In order to understand the discrepancy of the virus growth in cell
culture and the pathogenicity in mice, we measured the interferon β
promoter activity of AllU4, AllC4 andWSNwt in infected cells (Fig. 7A)
and NS(U4) and NS(C4) replicons (Fig. 7B). Interferon β promoter
activity of AllU4 (0.051±0.0084) was lower than that of WSNwt
WSNwt
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Fig. 6. Survival of mice infected with AllU4, AllC4 andWSNwt. Groups of four mice inoculated intranasally with 50 μl of 105, 104, and 103 PFU of WSNwt (A), All4U (B) and All4C (C).
Their survival status was monitored every day.
193H. Jiang et al. / Virology 408 (2010) 190–196(0.086±0.010, pb0.01). Interferon β promoter activity of AllC4
(0.179±0.013) was higher than that of WSNwt (pb0.005). Interferon
β promoter activity of NS(U4) replicon (0.194±0.012) was signiﬁ-
cantly lower than that of NS(C4) (0.248±0.009, pb0.005).Fig. 7. Interferon β promoter activity and NS1 protein. Interferon β promoter activity was m
infected cells (A), and NS(U4) and NS (C4) genomes (B). The ratio of NS1 protein to β-act
WSNwt (wt) infected cells (C). The position of protein standard marker (M) is indicated on t
are calculated from three independent measurements. *pb0.01, **pb0.005.Expression of NS1 protein
NS(U4) replicon was more active than NS(C4) replicon (Fig. 1).
Interferonα/β are induced by virus ssRNA and dsRNA (Yoneyama andeasured as the relative luciferase activity of AllU4 (AU4), AllC4 (AC4) and WSNwt (wt)
in was compared by Western blot (above the graph) of AllU4 (AU4), AllC4 (AC4) and
he left of the blot, and that of NS1 and β-actin is indicated on the right. The mean and SD
194 H. Jiang et al. / Virology 408 (2010) 190–196Fujita, 2009). NS(U4) replicon did not activate interferon β promoter
as high as NS(C4) although NS(U4) replicon produced more RNA
(Fig. 7B). Interferon production and signaling is inhibited by NS1
protein (Hale et al., 2008). Therefore, we compared the amount of NS1
in AllU4, AllC4 and WSNwt-infected cells by Western blot (Fig. 7C).
The ratio of NS1 to β-actin in the cells at 8 h post infection of AllC4
(1.1±0.18) was lower than that of WSNwt (1.5±0.05, pb0.05). That
of AllU4 (1.5±0.12) was similar to WSNwt.
Discussion
The highly conserved 5′ and 3′ ends of the inﬂuenza virus v- and
cRNA serve as the transcription promoter and the replication origin
(Deng et al., 2006; Fodor and Brownlee, 2002). The inﬂuenza genome
contains U or C at the 4th position of the 3′-end (Desselberger et al.,
1980; Robertson, 1979). U4 promoter enhanced transcription activity
by 20-fold in infected cells when C4 was changed to U4 in the NA
genome of WSN (Lee and Seong, 1998). In order to study the
difference betweenU4 and C4with regard to transcriptional promoter
and replication origin, we used replicon and in vitro transcription
systems. The replicon activity of C4 promoter was 28±6% of U4
(Fig. 1). Replicon activity represents transcription of the genome.
Therefore, we compared the promoter/origin activity of U4, C4 and
cRNA in vitro (Fig. 2). The biochemical promoter/origin activity
determined in this study was different from that by Lee and Seong
(1998) because they measured the amount of RNA in cells. Globin
mRNA-priming is an in vitro model of inﬂuenza virus transcription
and initiation de novo and with ApG is a model of replication. C4
showed weak activity in both transcription and replication, and the
replication activity of C4 was weaker than its transcription activity.
c84 showed less than 10% template activity of v84(U4).
However, large amount of vRNA was found in the infected cells
(Hatada et al., 1989; Lee and Seong, 1998). The mechanism of large
amount of vRNA synthesis from cRNA is the strong afﬁnity of vRNA
with RdRp. From the heparin inhibition experiment, RdRp bound to
vRNA even after transcription and replication ﬁnished (Fig. S4; Zhang
et al., 2010a).
Surprisingly, the puriﬁed RdRp used globin mRNA as a primer for
the c84 template (Fig. 2) although Honda et al. (2001) failed to
demonstrate the cleavage of cap-1 RNA of the complementary RNA
template, c53. Both c53 and c84 share the identical 3′ and 5′-
sequences and served as the template for inﬂuenza RdRp (Kobayashi
et al., 1996). The reason of the controversial results is likely due to the
difference of the activity and purity of RdRp. Globin mRNA-primed
transcription of c84 was conﬁrmed by the single-round transcription
assay with heparin (Fig. 3). The relative activity of globin mRNA-
primed transcription of c84 was lowest because it was not a template
for viral mRNA transcription. v84(U4), v84(C4), and c84 used the
same cleaved mRNA primers because their product size was identical.
Cap 1-priming is concluded to be a biochemical characteristic of
inﬂuenza virus RNA polymerase.
The promoter binding activity of C4 by RdRp was about 42% of U4
(Fig. 4), which was higher than its transcription/replication activity
(Fig. 2), indicating that C4 promoter/origin has lower initiation
activity than U4.
Finally, the role of the U4 and C4 promoter/origin in viral infection
was analyzed. The ratio of U4 and C4 promoter/origin in inﬂuenza
genomes varies in inﬂuenza isolates, andWSNhas 4 and 5 genomes that
contain C4, respectively (Crescenzo-Chaigne et al., 2002). Then, WSN
mutants containing the U4 (AllU4) or C4 (AllC4) promoter/origin in all
8 genome segments were reconstituted (Fig. 5). AllU4 showed the same
growth kinetics as WSNwt, and plateaued at 48 h after infection.
However, its titer was 760 times higher than that of wild type. AllC4
showed slightly slower growth than WSNwt and plateaued at 60 h pi,
when their titers were similar. The nucleotide sequences of U4 and C4
were stable, at least by the end of the growth kinetic experiments. AllU4grew more than NAU4 virus, which does not agree with the previous
idea of the C4 promoter economizing viral protein expression (Lee and
Seong, 1998). Furthermore, AllC4 did not attenuate.WSNwt contains C4
in PB2, PB1, PA, and NA. The C4 promoter/origin in NA is likely to
attenuate virus growth because low expression of RNA polymerase
subunits can supply sufﬁcient amounts of RNA polymerase in infected
cells (Inglis and Mahy, 1979; Lamb and Choppin, 1976). Under low
expression of NA by C4 promoter/origin, the expression of NA plays a
critical role onvirion formationbecause bothHAandNAproteins control
virion assembly andbudding (Chen et al., 2007). From the in vitro data of
promoter/origin function and their effect on virus replication in the cells,
it is concluded that the transcription promoter activity of C4 is 37% and
its replicationorigin activity is 21–24%ofU4, and that the virus growth in
the cells is affected simply by the strength of promoter/origin.
However, their pathogenicity in mice was different from their
growth in the cells. The pathogenicity of AllU4 in mice was lower than
that ofWSNwt (Fig. 6).Whenmicewere infectedwith viruses, infection
gradually expanded from the trachea to the deeper sections of the lungs
(Manicassamy et al., 2010). This controversial phenomenon can be
explained by innate immunity induced by inﬂuenza infection. Inﬂuenza
virus activated toll-like receptor (TLR) signaling pathway (Wong et al.,
2009). AllU4 produces more ss and double stranded (ds) RNA than
WSNwt in the infected cells. In the AllU4-infected mice, innate
immunity except type I interferon may be activated more than
WSNwt-infected ones through TLR3 and 7 by ss and dsRNA (Kawai
and Akira, 2010), and the AllU4 infected mice survived more than
WSNwt-infected ones (Fig. 6). Inﬂuenza infection upregulated TLR3 and
induced TLR3 mediated host immune responses (Le Gofﬁc et al., 2006;
Le Gofﬁc et al., 2007). However, interferon β induction of AllU4 was
lower thanWSNwt and that of NS(U4) replicon was also lower than NS
(C4) (Fig. 7). Type I interferon is inducted by the signal transduction
pathway through retinoic-acid inducible gene-I (RIG-I) which is
triggered by 5′-triphosphate containing inﬂuenza RNA (Kato et al.,
2006; Loo et al., 2008; Yoneyama and Fujita, 2009). However, RIG-I is
inhibited byNS1 protein (Opitz et al., 2007). In AllU4 infected cellsmore
NS1 proteins, which inhibited the RIG-I derived signal transduction
pathway including type I interferon induction, were produced than
WSNwt although AllU4 producedmore vRNA to stimulate RIG-I (Fig. 7).
U4 promoter/origin is stronger than C4. However, the virus which
has the strongest promoter/origin combination does not exist in the
nature and WSN contains both U4 and C4 promoter/origin in its
genome segments (Desselberger et al., 1980; Robertson, 1979). The
combination of U4 and C4 promoter/origin of inﬂuenza viruses has
been selected by the host defense and virus interaction.
Materials and methods
Cell culture
293 T and MDCK cells were maintained in Dulbecco's modiﬁed
Eagle'sminimal essential medium (DMEM) containing 10% and 5% fetal
bovine serum (FBS, GIBCO), respectively, 50 U of penicillin (Invitrogen),
50 μg of streptomycin (Invitrogen), and 0.1 mg/ml kanamycin (Invitro-
gen). TN5 cells were maintained in SF900II containing 1% FBS
(Invitrogen), 50 U/ml of penicillin (Invitrogen), 50 μg/ml of streptomy-
cin (Invitrogen), 0.1 mg/ml kanamycin (Invitrogen) and 10 U/ml
heparin (Shanghai First Biochemical Pharmaceutical Co.), respectively.
Replicon assay
ppolIPR8NSC4luc,which containsC insteadofUat the 4thnucleotide
position from the 3′ terminus, was constructed from ppolIPR8NSluc
(Toyoda et al., 2003) by PCR ampliﬁcation using the primers PR8NSC4 f
and PR8NS r (Supplementary Table 1). A standard replicon assay was
performedbymeasuring luciferase activity using theDual-Glo luciferase
assay kit (Promega) and a GloMax 96 Microplate Luminometer
195H. Jiang et al. / Virology 408 (2010) 190–196(Promega) at 24 h after transfection of 0.1 μg of pCPB2, pCPB1, pCPA,
pCNP (Toyoda et al., 1996), ppolINSluc, or ppolIPR8NS4Cluc and 0.01 μg
of pRLSV40 (Promega) using Lipofectamine2000 (Invitrogen) as previ-
ously published (Toyoda et al., 2003).
Expression and puriﬁcation of inﬂuenza virus RdRp
Inﬂuenza virus RdRp was puriﬁed as previously published (Zhang
et al., 2010a). Brieﬂy, TN5 cells were infected with Bac18xHis–PR8PB2
(MOI 5), BacPR8PB1 (MOI 4) and BacPR8PA (MOI 2). At four days after
infection, the inﬂuenza virus RdRp was extracted from the nuclei with
the extraction buffer [500 mMNaCl, 20 mMHEPES–NaOH (pH 7.9), 25%
glycerol, 1.5 mM MgCl2, 0.1% mercaptoethanol, and 1 tablet/25 ml
EDTA-free protease inhibitor cocktail tablets (Roche)] by homogeniza-
tion in a Dounce homogenizer for 15 strokes with a tight pestle. After
gentle extraction at 4 °C for 30 m by rotation, the cells were centrifuged
in a Beckman 45 Ti rotor at 142 k×g for 30 m. The nuclear extract was
appliedontoProBond(Invitrogen)andeluted at 250 mMimidazole after
the resin was washed with 10 column volumes of 100 mM imidazole,
followed by dialysis against BC200 [20 mM Tris–HCl (pH 7.9), 200 mM
NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, and 10% glycerol].
In vitro transcription
Inﬂuenza RdRp (100 nM) were incubated in 50 mM Tris–HCl (pH
8.0), 8 mMMgCl2, 150 mMNaCl, 2 mMDTT, 0.5 mMATP, 0.5 mM CTP,
0.5 mM GTP, 0.05 mM [α-32P] UTP, 0.1 mM ApG or 0.01 mg/ml globin
mRNA, 2000 U/ml RNase inhibitor and 200 nM v84 and c84 model
template RNA. A hundred nM of homopolymeric RNA templates, A32,
U35 and C27, were transcribed with 0.1 mM UpU, ApA and GpG, in
0.05 mM [α-32P] ATP, [α-32P] UTP and [α-32P] GTP, respectively. The
product was analyzed by 6% (for v84 and c84) and 15% (for
homopolymeric RNA templates) PAGE containing 8 M urea, followed
by image analysis with Typhoon Trio plus (GE).
Single-round transcription assay
Ten μM of c84 RNA and 0.5 μg globin mRNA were incubated in
50 mM Tris–HCl (pH 8.0), 8 mM MgCl2, 150 mM NaCl, 2 mM DTT,
0.5 mM ATP, 0.5 mM CTP, 0.5 mM GTP, 0.05 mM [α-32P] UTP, 2000 U/
ml RNase inhibitor, and 5 μM of inﬂuenza virus RdRp with or without
50 μg/ml heparin.
Model RNA template
Model RNA templates, v84(4U), v84(4C), and c84, were prepared
using MegaShortScript (Ambion) using MboII digested pT7/v84, pT7/
v84(4C), and pT7/c84 (Kobayashi et al., 1996).
Competitive RNA UV-crosslink assay
0.2 pmol RdRp and 0.2 pmol [32P]v84(4U) with 0.1, 0.2, 0.4, and
0.8 pmol of v84(4U) or v84(4C) were incubated in 10 μl of 50 mM
Tris–HCl (pH 8.0); 8 mMMgCl2, 150 mM NaCl and 2 mM DTT at 25 °C
for 30 m. The reactionmixturewas irradiated at a distance of 10 cm for
20 m on ice with a UV lamp (Sanyo). After irradiation, the samples
were digested for 30 m at 37 °Cwith 0.2 μg of RNase A. The crosslinked
products were analyzed by electrophoresis on SDS–7.5% PAGE. After
electrophoresis, the gels were dried and analyzed with Typhoon Trio
plus image analyzer (GE). In reverse, 0.2 pmol [32P]v84(4C) was
competed with 0.1, 0.2, 0.4, and 0.8 pmol of v84(4U) or v84(4C).
In vitro mutagenesis
A C→Umutation was introduced into ppolI-WSN-PB2, PB1, PA, and
NA, andaU→Cmutationwas introduced intoppolI-WSN-HA, ppolI-NP,ppolI-M, ppolI-NS, and ppolINSluc using the oligonucleotides listed in
Table S1 with the QuickChange II Site-Directed Mutagenesis kit
(Stratagene). Each mutation was conﬁrmed by sequencing.
Reconstitution of the inﬂuenza virus and plaque forming assay
Inﬂuenza virusWSN strain (WSNwt) and its mutants (AllU4, AllC4,
NAU4 and NSU4 viruses) were reconstituted by transfection of the
wild type and the mutant genomes of ppolI-WSN-PB2, ppolI-WSN-
PB1, ppolI-WSN-PA, ppolI-WSN-HA, ppolI-WSN-NP, ppolI-WSN-NA,
ppolI-WSN-M, and ppolI-WSN-NS with pCPB2, pCPB1, pCPA, and
pCNP into 293T cells (Neumann et al., 1999; Toyoda et al., 1996) using
Lipofectamine2000 (Invitrogen). At 72 h after transfection, the
reconstituted viruses were recovered from culture media and titrated
using a plaque forming assay in MDCK cells and stored at −80 °C.
Virus growth assay
MDCK cells in a 12-well plate were infected with reconstituted
inﬂuenza viruses at anMOI of 0.01 at 37 °C for 1 h. After being washed
ﬁve timeswith PBS, the cellswere incubatedwith 2.5 ml of DMEM, and
2% FBS at 37 °C. The supernatants were harvested at 0, 8, 16, 24, 36, 48,
and 60 h after infection and stored at −80 °C. The viruses in the
supernatantswere titratedusing a plaque forming assay inMDCK cells.
Sequence determination of the reconstituted viruses
Viral RNA were extracted with Trizol (Invitrogen) and puriﬁed by
ethanol precipitation. The puriﬁed genome RNA were poly A tailed by
5 U of poly(A) polymerase (New England Biolab) in 50 mM Tris–HCl
(pH 7.9), 250 mM NaCl, 10 mM MgCl2, and 1 mM ATP at 37 °C for
10 min. After the poly(A) tailed genome RNA had been puriﬁed by
phenol/chloroform extraction and ethanol precipitation, the 3′-ends of
the genomic cDNAwere collected using a 3′-Full RACE Core set (Takara)
with oligonucleotides listed in Table S2. After the cDNAhad been cloned
in pGEMT-easy vector (Promega), their sequences were conﬁrmed.
Mice infection
Groups of four six-week-old female Balb/C mice (Sino-British
Laboratory Animal) were anaesthetized using ether and inoculated
with 50 μl of 105, 104, and 103 PFU ofWSNwt, All4U and All4C by nasal
dropping. Their survival rates were monitored every day for 14 days
after infection and 50% lethal dose (LD50) was calculated by the
method of Reed and Muench (1938).
Interferon promoter assay
p-125Luc (Yoneyama et al., 1996) was a kind gift from Dr. T. Fujita.
293T cells in 24-well plate were transfected with 0.1 μg of p-125Luc
and 0.01 μg of pRLSV40. The cells were infected with an MOI of 1 of
WSN, AllU4 and AllC4 at 16 h after transfection. At 8 h after infection,
the cells were harvested and the promoter activity of interferon βwas
measured as the luciferase activity using the Dual-Glo luciferase assay
kit. Luciferase activity was measured at 16 h after transfection of
0.1 μg of pCPB2, pCPB1, pCPA, pCNP, p-125Luc, 0.01 μg of pRLSV40, and
ppolI-WSN-NSwt(U4) or ppolI-WSN-NS(C4). The luciferase activity of
p-125Luc transfected 293T cells was subtracted from all of the data.
Measurement of NS1 by Western blot
The amount of NS1 in the cells infected by for 8 h was analyzed by
Western blot using anti-NS1 antibodies (Antibody Center, Shanghai
Institute of Biological Sciences). Proteins were blotted onto nitrocel-
lulose membranes (Millipore) by semidry electroblotting (BioRad)
after 12.5% SDS-PAGE. After the blotted membranes were blocked
196 H. Jiang et al. / Virology 408 (2010) 190–196with 10% skim milk in 20 mM Tris–HCl (pH 7.5), 150 mM NaCl, and
0.02% Tween 20 (TBST), Western blot was performed using rabbit
anti-NS1 (1:500), and anti-actin antibodies (1:50, Sigma) as primary
antibodies. After the membranes were incubated with alkaline
phosphatase-bound anti-rabbit IgG or anti-mouse IgG (1:7500,
Promega), the position of the bound antibodies was visualized with
nitroblue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl phos-
phate (BCIP, Promega).
Chemicals and radioisotopes
Globin mRNA, heparin, UpU and Tris (Trizma) were purchased
from Sigma; nucleotides were from GE; [α-32P]UTP, [α-32P]ATP and
[α-32P]GTPwere fromNew England Nuclear; and synthetic oligo RNA,
dinucleotide ApA and GpG, human placental RNase inhibitor, RNase A
and restriction enzymes were from Takara.
Statistical analysis
Statistical data were evaluated by Student's t test.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2010.09.022.
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